NCT02822495
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Registry record
- Lead sponsor
- Atara Biotherapeutics
- Conditions
- Epstein-Barr Virus (EBV) Infections; Lymphoproliferative Disorders; EBV+ Associated Lymphoma; EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Epstein-Barr Viremia
- Primary completion
- Not registered
- Completion
- Locked
- Start
- Locked
- Enrollment
- Locked
- Interventions
- Locked
- Study type
- Locked
- Results on the registry
- Locked
- Record last updated
- Locked
Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerRecorded changes
0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.
Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.